CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Nanexa AB is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Nanexa AB
Virdings Alle 32B
Phone: +46 18100300p:+46 18100300 UPPSALA, 754 50  Sweden Ticker: NANEXANANEXA

Business Summary
Nanexa AB is a Sweden-based company engaged in the drug delivery systems industry. The Company specializes in the nanotechnology and research and development in life science. Its products portfolio is comprised of PharmaShell, a drug delivery system that allows for targeting and dosing of drugs; antifungal coating, a system that protects medical products from the in-growth of fungi; and low-friction coating for peripheral venous catheters.
(Source: 10-K405)

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
9/30/202412/31/2023Yes----

General Information
Number of Employees: 16 (As of 9/30/2024)
Outstanding Shares: 135,695,626 (As of 9/30/2024)
Stock Exchange: STO


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, November 20, 2024